Navigation Links
AACR: Positive data supports advancing BIND-014 to phase 2 clinical trials for solid tumors
Date:4/9/2013

Cambridge, MA, April 9, 2013 BIND Therapeutics, a clinical-stage biopharmaceutical company developing a new class of highly selective targeted and programmable therapeutics called AccurinsTM, announced today that positive Phase 1 clinical data for BIND-014, the company's lead drug candidate, were presented today in an oral presentation at the American Association for Cancer Research (AACR) 2013 Annual Meeting.

Clinical investigators presented the Phase 1 results with BIND-014, its targeted docetaxel Accurin, in 28 heavily-pretreated patients with advanced or metastatic solid tumors. In the study, BIND-014 was shown to be generally safe and well-tolerated at the established maximum tolerated dose of 60 mg/m2 and showed encouraging signs of anti-tumor activity including one complete response, three partial responses and five patients with stable disease lasting at least four cycles (> 12 weeks). In addition, the pharmacokinetic (PK) profile of BIND-014 was substantially different from the published PK of conventional docetaxel.

"This Phase 1 trial has successfully established the safety and tolerability profile and maximum tolerated dose of BIND-014 in patients with advanced or metastatic solid tumor cancers," commented Daniel D. Von Hoff, M.D., F.A.C.P., Principal Investigator for the study and Physician-in-Chief and Distinguished Professor at the Translational Genomics Research Institute (TGen) and the Scottsdale Clinical Research Institute. "There is a critical need for targeted treatment options for patients with difficult to treat solid tumors and we look forward to further evaluating the potential of BIND-014 in patients with specific solid tumor types in the near future."

"In addition to confirming the safety, tolerability and maximum tolerated dose of BIND-014, these data also provide encouraging signs of anti-tumor activity in a variety of solid tumors," said Gregory Berk, M.D., Chief Medical Officer of BIND Therapeutics. "Based on these dat
'/>"/>

Contact: Kathryn Morris
kathryn@theyatesnetwork.com
845-635-9828
The Yates Network
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Positive stress helps protect eye from glaucoma
2. False-Positive Mammogram Results May Turn Out Not to Be: Study
3. The bright side of death: Awareness of mortality can result in positive behaviors
4. Decision support system translates into high percentage of positive chest CT examinations
5. Breast cancer patients with positive ultrasound guided axillary node biopsy need dissection
6. Automated insulin dosage titration system demonstrates positive clinical study results
7. Lung changes are present in nearly half of ACPA positive RA patients at disease onset
8. NIH study finds HIV-positive young men at risk of low bone mass
9. Surgeons Seek Repeal of Transplant Ban Between HIV-Positive People
10. Higher levels of public reimbursement positively influence national birth rates and reduce unmet needs in subfertile populations
11. HPV testing in HIV-positive women may help reduce frequent cervical cancer screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... see, swim in, and soak in what Michael Phelps trains in ... to be the most decorated athlete of all time. The Michael ... The Toledo Hot Tub, Swim Spa, Pool & Patio Show this ... Sales Manager for Master Spas, said, "The Hot Tub, Swim Spa, ... of great products and build your dream backyard at deep, deep ...
(Date:7/24/2014)... Henderson, NV (PRWEB) July 24, 2014 ... at 9:00 am EDT, An archived recorded version can ... at http://www.stocktraderstalk.com , following the interview. , ... CipherShop Division which provides commercial quality, advanced, digital security ... HIPAA and SOX and their CipherLoc product suite offers ...
(Date:7/24/2014)... Comparemedicalinsurance.info has released a new blog post explaining how ... problems. , A pre-existing medical condition can make ... exam life insurance plans offer a simplified underwriting process ... , No medical exam life insurance plans can ... others will insure the client for an unlimited period. ...
(Date:7/24/2014)... Osteoporosis is one of the most devious diseases which affect ... research goes, there are now many factors which can ... and lack of calcium intake. Older people now live in ... in their lives. , However, that does not mean there ... a former sufferer who had managed to rebuild her life ...
(Date:7/24/2014)... A study published in the journal of ... Yin of NYU’s Langone Medical Center. She found that ... to confusion over liquid dosages alone., From confusion over differing ... children, Yin warns it often leads to parents double-dosing their ... of parents in the study incorrectly measured out the actual ...
Breaking Medicine News(10 mins):Health News:See the New Michael Phelps Swim Spas and Hot Tubs at The Toledo Hot Tub, Swim Spa, Pool & Patio Show at the Lucas County Rec Center this Weekend 2Health News:Cloud Medical Doctor Software Corporation, CEO, Michael DeLaGarza, Exclusive Interview on StockTradersTalk.com 2Health News:Cloud Medical Doctor Software Corporation, CEO, Michael DeLaGarza, Exclusive Interview on StockTradersTalk.com 3Health News:Life Insurance Without Examinations for Clients Who Have Pre-Existing Medical Conditions 2Health News:The Truth About Osteoporosis Review | The Ultimate Secret to Treating Osteoporosis in a Natural and Safe Manner – Vinamy.com 2Health News:The Truth About Osteoporosis Review | The Ultimate Secret to Treating Osteoporosis in a Natural and Safe Manner – Vinamy.com 3Health News:Many Parents Confused by Over-The-Counter Medications and OTCPlus App Solves This Problem 2
... of service within past year, study found , , MONDAY, ... receive the appropriate amount of preventive health services, even ... behaviors and discourage damaging behaviors that can affect teens ... finds. , The University of California, San Francisco, researchers ...
... Loss Costs Economy up to $15 Billion Each Year According ... than ever, Americans need their shut-eye. Unfortunately, sleep is usually ... is short and stress is high. In a turbulent economy, ... a few nights per week , according to a 2009 ...
... March 30 Amylin Pharmaceuticals, Inc. (Nasdaq: ... at the 2009 Annual Meeting of Stockholders. Over the ... consultation with other independent directors, engaged in a rigorous ... experienced nominees that the Board strongly believes will best ...
... 30 NuVasive, Inc. (Nasdaq: NUVA ), ... minimally disruptive surgical treatments for the spine, announced today ... of Osteocel, NuVasive has accelerated the transfer of the ... OSIR ) to its own exclusive supply chain. ...
... New Products Including Completing CE Mark, ... Neovasc Inc. (TSXV: NVC) today announced that it intends ... million units at the price of $0.21 per unit ... of the offering will be used for continued development ...
... LCA-Vision Inc. (Nasdaq: LCAV ), a leading ... Plus (R) brand, today announced that, according to a ... Commission, the dissident Joffe Group announced it has terminated ... that the Group has disbanded. Additionally, the Joffe ...
Cached Medicine News:Health News:Most Teens Aren't Getting Preventive Health Care 2Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 2Health News:It Pays to Sleep: Prioritize Rest to Boost Health, Morale and Revenue 3Health News:Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders 2Health News:Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders 3Health News:Amylin Pharmaceuticals Announces Slate of Directors for Annual Meeting of Stockholders 4Health News:Long Term Supply of Osteocel(R) Plus Solidified Without Ownership of Processing Facility 2Health News:Long Term Supply of Osteocel(R) Plus Solidified Without Ownership of Processing Facility 3Health News:Long Term Supply of Osteocel(R) Plus Solidified Without Ownership of Processing Facility 4Health News:Neovasc to Raise $2 Million in Non-Brokered Private Placement 2Health News:Neovasc to Raise $2 Million in Non-Brokered Private Placement 3Health News:LCA-Vision Announces Termination of Consent Solicitation and Withdrawal of Dissident Slate of Director Nominees 2
(Date:7/24/2014)... N.J., July 24, 2014 , Revenues ... year , Adjusted diluted EPS from continuing operations of ... EPS from continuing operations of $0.92, 7% below prior year ... versus prior year , Full year 2014 revenues now ... to 4% previously , Full year 2014 adjusted diluted ...
(Date:7/24/2014)... HIGHLIGHTS:Q2 2014 Results (all percentage changes are against ... 3% to $701 million.  Sales grew organically by 2%, and ... to sales growth. , By business unit, organic sales ... in SAFC Commercial. , Reported diluted EPS was $1.11 ... Adjusted diluted EPS in Q2 2014 was also $1.11 compared ...
(Date:7/24/2014)... July 24, 2014   ndd Medical Technologies , ... employing precise ultrasound technology, announced that its EasyOne Pro ... measure Carbon Monoxide Diffusing Capacity (DLCO) for phase 2 ... study of Chronic Obstructive Pulmonary Disease (COPD) ever undertaken. ... in the U.S. and affects millions of people worldwide.  ...
Breaking Medicine Technology:Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 2Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 3Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 4Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 5Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 6Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 7Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 8Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 9Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 10Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 11Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 12Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 13Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 14Sigma-Aldrich (NASDAQ - SIAL) Reports Record Q2 2014 Results With Sales Of $701 Million And Diluted EPS Of $1.11. Raises Lower-End Of Full-Year 2014 Adjusted Diluted EPS Guidance To A New Range Of $4.32 To $4.40. 15
... SUTIMCo International, Inc. (Pink Sheets: SUTI ) ... corporate executive to the 125th Annual Meeting of The ... in New Orleans.   For over a century, AOAC ... well as proficiency testing and accreditation programs for laboratories. ...
... 2011 HemaQuest Pharmaceuticals, Inc. (HemaQuest), a biotechnology company ... disorders, announced today that it has completed enrollment in ... patients with sickle cell disease. The study, initiated in ... patients in clinical sites in the US, Canada, Jamaica, ...
Cached Medicine Technology:SUTIMCo International Inc. to Attend 125th AOAC Annual Meeting 2SUTIMCo International Inc. to Attend 125th AOAC Annual Meeting 3HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease 2HemaQuest Pharmaceuticals Completes Patient Enrollment in Phase 2 Clinical Study of HQK-1001 in Patients With Sickle Cell Disease 3
The vertebral body replacement (VBR) is used for the anterior thoracic and lumbar spine. It is intended for use in the thoracic and lumbar spine to replace a collapsed, damaged, or unstable vertebral...
... Ocelot stackable cage system provides anterior ... or total vertebrectomies from T1 to L5. ... Peek Carbon fiber polymer cages that are ... patient needs. The Peek Carbon fiber reinforced ...
... cage system provides anterior column support for ... from T1 to L5. The system consists ... polymer cages that are stacked to a ... Peek Carbon fiber reinforced polymer material emulates ...
... regeneration scaffold. Its highly ... ensures ideal osteoconductivity, while ... maximizes permeability even after ... most meaningful measure of ...
Medicine Products: